In addition, to the best of our knowledge, SAFE-PCI was the first trial to evaluate kidney injury in the context of PCI through assessment of NGAL, as an early predictor of CI-AKI, which is a biomarker more accurate than serum creatinine. This evidence concerns the gene LCN2 and acute kidney injury.